Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 4/20 | 0.45 |
| ▸ | CTSS | P25774 | 4/20 | 0.45 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31454371 | 0.90 | SYK (0.53) | SYKCTSBCTSSCTSLSMN1; SMN2 | |
| SCHEMBL1305698 | 0.87 | CHRM1 (0.50) | CTSBCTSSCTSLSMN1; SMN2MEN1 | |
| SCHEMBL1308680 | 0.85 | CTSL (0.46) | CTSBCTSSCTSLSMN1; SMN2MEN1 | |
| SCHEMBL19189058 | 0.85 | SYK (0.47) | SYKCTSBCTSSCTSLSMN1; SMN2 | |
| SCHEMBL22394860 | 0.84 | SYK (0.43) | SYKCTSBCTSSCTSLSMN1; SMN2 | |
| SCHEMBL2394376 | 0.84 | CTSS (0.53) | SYKCTSBCTSSCTSLSMN1; SMN2 | |
| SCHEMBL1305844 | 0.83 | CTSL (0.48) | CTSBCTSSCTSLSMN1; SMN2NPC1 | |
| SCHEMBL27231928 | 0.82 | SYK (0.53) | SYKCTSBCTSSCTSLSMN1; SMN2 | |
| SCHEMBL10152374 | 0.82 | SYK (0.48) | SYKCTSBCTSSCTSLSMN1; SMN2 | |
| SCHEMBL7352450 | 0.81 | CTSS (0.60) | SYKCTSBCTSSCTSLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1712547-B1 | BICYCLOESTER DERIVATIVE | KYORIN SEIYAKU KK (JP) | 2011-12-14 | — | — | EP | disclosed |
| US-8053465-B2 | Bicycloester derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-08 | — | — | US | disclosed |
| US-7754757-B2 | Bicycloester derivative | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20100093825-A1 | Bicycloester derivative | FUKUDA YASUMICHI | 2010-04-15 | — | — | US | disclosed |
| US-20080146818-A1 | Dipeptidylpeptidase IV (DPP-IV) inhibitory activity; (2S,4S)-1-[[N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)); diabetes | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-06-19 | — | — | US | disclosed |
| EP-1712547-A1 | BICYCLOESTER DERIVATIVE | Kyorin Pharmaceutical Co., Ltd. (JP) | 2006-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093825-A1 | Bicycloester derivative | DPP4, DPP7, DPP3 | SYK 4170/4885CTSB 1041/4885CTSS 644/4885 |
| US-20080146818-A1 | Dipeptidylpeptidase IV (DPP-IV) inhibitory activity; (2S,4S)-1-[[N-(4-ethoxycarbonylbicyclo[2.2.2]oct-1-yl)amino]acetyl]-4-fluoropyrrolidine-2-carbonitrile)); diabetes | DPP4, DPP7, DPP3 | SYK 4444/4885CTSB 392/4885CTSS 360/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.